Managing phosphate retention: Is a change necessary?

Nephrology Dialysis Transplantation

Volumn 15, Issue 11, 2000, Pages 1738-1742

  Salusky, Isidro B ^a,b   Goodman, William G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALUMINUM; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; DOXERCALCIFEROL; FERRIC HYDROXIDE; FERRIC POLYMALTOSE COMPLEX; LANTHANUM CHLORIDE; OSTEOPONTIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; DIET RESTRICTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; NONHUMAN; OSTEOPOROSIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROGNOSIS; SECONDARY HYPERPARATHYROIDISM; TOXICITY;

EID: 0033756063     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.11.1738     Document Type: Article

References (58)

1. Causes of death
2. Patient mortality and survival
3. Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future directions
4. ″U″ curve association of blood pressure and mortality in hemodialysis patients
5. An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors
6. Pathogenesis of glucose intolerance in uremia
7. The uremic dyslipidemia: A cross-sectional and longitudinal study
8. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
9. Accelerated atherosclerosis in prolonged maintenance haemodialysis
10. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?
11. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic haemodialysis patients: A national study
12. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism
13. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
14. Arterial stiffening and vascular calcifications in end-stage renal disease
15. A clinical approach to the uraemic patient with extraskeletal calcifications
16. Soft tissue calcification in pediatric patients with end-stage renal disease
17. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease
18. Kaik metastasen
19. Evolution of bone disease over 10 years in 135 patients with terminal renal failure
20. Myocardial calcification and cardiac dysfunction in chronic renal failure
21. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure
22. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics
23. Bone morphogenetic protein expression in human atherosclerotic lesions
24. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify
25. Ethnic origin and serum levels of 1α,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography
26. Atherosclerotic calcification: Relation to developmental osteogenesis
27. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis
28. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification
29. Active serum vitamin D levels are inversely correlated with coronary calcification
30. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients
31. Prognostic significance of coronary calcifications in patients undergoing coronary angiography: A multicenter study
32. On the prevention of secondary hyperparathyoidism in experimental chronic renal disease using ″proportional reduction″ of dietary phosphorus intake
33. Renal osteodystrophy in adults and children
34. Metabolic studies of low protein diets in uremia: II. Calcium, phosphorus and magnesium
35. Are we mismanaging calcium and phosphate metabolism in renal failure?
36. Control of serum phosphorus without any phosphate binders in patients treated with nocturnal haemodialysis
37. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease
38. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis
39. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis
40. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia and hyperparathyroidism in uremia
41. Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis
42. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfa-calcidiol
43. Osteoporosis
44. Optimal Calcium Intake
45. Dose dependency of calcium absorption: A comparison of calcium carbonate and calcium citrate
46. The treatment uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study
47. Oral and parenteral calcitriol for the management of end-stage renal disease
48. RenaGel, a novel calcium- And aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers
49. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
50. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
51. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in haemodialysis patients
52. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
53. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients
54. New phosphate binding agents: Ferric compounds
55. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy
56. 19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on haemodialysis
57. One-alpha-hydroxyvitamin D2 (doxercalciferol) effectively and safely suppresses intact parathyroid hormone levels in haemodialysis patients with moderate to severe secondary hyperparathyroidism: Results of a double-blinded, placebo-controlled study
58. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management